Anbio Biotechnology (NNNN) Total Current Liabilities (2023 - 2025)

Anbio Biotechnology has reported Total Current Liabilities for 3 years, with the latest figure at $87836.0 in Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 94.92% year-over-year to $87836.0 in Q4 2025; TTM through Dec 2025 was $87836.0, a 94.92% decrease from a year earlier, with the FY2025 full-year figure at $87836.0, down 94.92% from the prior year.
• Total Current Liabilities was $87836.0 for Q4 2025 at Anbio Biotechnology, down from $131127.0 in the prior quarter.
• The five-year high for Total Current Liabilities was $1.7 million in Q4 2024, with the low at $87836.0 in Q4 2025.
• Average Total Current Liabilities over 3 years is $735564.2, with a median of $562093.5 recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 74.23% in 2024, then sank 94.92% in 2025.
• Over 3 years, Total Current Liabilities stood at $993060.0 in 2023, then soared by 74.23% to $1.7 million in 2024, then tumbled by 94.92% to $87836.0 in 2025.
• The last three Total Current Liabilities figures came in at $87836.0 (Q4 2025), $131127.0 (Q2 2025), and $1.7 million (Q4 2024), per Business Quant data.